Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults. Lasmiditan Succinate was developed by Eli Lilly And Company.
The API has now reached off-patent status, after being launched in 2019.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Lasmiditan Succinate and many others, contact info@pharmacheminvestor.com